Health adults
Conditions
Interventions
Test drugs are GLA-ALPHA combination ophthalmic solution and Ailamide combination opthalmic suspension and Aiphagan opthalmic suspension.
One of the test drugs will be instilled in the eye to be ev
Sponsors
Inatani Masaru
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Received sufficient explanation for participation and have obtained the subject's free and voluntary written consent. 2)Healthy adults over 18 years old, regardless of gender
Exclusion criteria
Exclusion criteria: 1)Participation in this study is deemed inappropriate by the principal investigator 2)Eye diseases 3)Impossibility observing aqueous veins 4)Pregnant, breastfeeding, may be pregnant, or wish to become pregnant during the research period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aqueous column changes in the episcleral veins 2 hours after instillation of ripasudil versus latanoprost | — |
Secondary
| Measure | Time frame |
|---|---|
| Aqueous column changes in the episcleral veins 8 hours after instillation, intraocular pressure changes (2 and 8 hours after instillation), questionnaire: Score evaluation of usability (eye irritation, blurred vision, conjunctival congestion, bitter taste), adverse events. | — |
Contacts
Public ContactMasaru Inatani
University of Fukui Hospital
Outcome results
None listed